Balance Sheet

Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt repayments

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization Cost of Revenue EBIAT Gross Profit Leases Long-Term Debt Issuances Long-Term Debt Repayments Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding Short-Term Debt repayments

BioNexus Gene Lab (BGLC) Short-Term Debt repayments (2018 - 2025)

BioNexus Gene Lab's Short-Term Debt repayments history spans 5 years, with the latest figure at -$497.0 for Q4 2025.

Quarterly results put Short-Term Debt repayments at -$497.0 for Q4 2025, up 64.17% from a year ago — trailing twelve months through Dec 2025 was -$164679.0 (up 17.14% YoY), and the annual figure for FY2025 was $32305.0, up 712.7%.
Short-Term Debt repayments for Q4 2025 was -$497.0 at BioNexus Gene Lab, down from $34187.0 in the prior quarter.
In the past five years, Short-Term Debt repayments ranged from a high of $34187.0 in Q3 2025 to a low of -$196982.0 in Q3 2024.